Format

Send to

Choose Destination
Intensive Care Med. 2019 Jan 21. doi: 10.1007/s00134-019-05529-w. [Epub ahead of print]

Nasal high-flow preoxygenation for endotracheal intubation in the critically ill patient: a randomized clinical trial.

Author information

1
Service de Réanimation Médico Chirurgicale, USC, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 9, France. cguitton@ch-lemans.fr.
2
Médecine Intensive Réanimation, INSERM CIC 1415, Centre Hospitalier Universitaire de Tours, Centre d'Etude des Pathologies Respiratoires INSERM U1100, Tours University, Tours, France.
3
Plateforme de Méthodologie et de Biostatistique, Centre Hospitalier Universitaire de Nantes, Nantes, France.
4
Médecine Intensive Réanimation, Centre Hospitalier de La Roche sur Yon, La Roche-Sur-Yon, France.
5
Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Rennes, Rennes, France.
6
Médecine Intensive Réanimation, Centre Hospitalier Universitaire de Brest, Brest, France.
7
Service d'Anesthésie-Réanimation Chirurgicale, Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France.
8
Service de Réanimation Médico Chirurgicale, USC, Centre Hospitalier du Mans, 194 Avenue Rubillard, 72037, Le Mans Cedex 9, France.
9
Médecine Intensive Réanimation, Hôtel-Dieu, Centre Hospitalier Universitaire de Nantes, Nantes, France.

Abstract

PURPOSE:

Preoxygenation with high-flow therapy by nasal cannulae (HFNC) is now widespread in the intensive care unit (ICU). However, no large randomized study has assessed its relevance in non-severely hypoxemic patients. In a randomized controlled trial (PROTRACH study), we aimed to evaluate preoxygenation with HFNC vs. standard bag-valve mask oxygenation (SMO) in non-severely hypoxemic patients during rapid sequence intubation (RSI) in the ICU.

METHODS:

Randomized controlled trial including non-severely hypoxemic patients requiring intubation in the ICU. Patients received preoxygenation by HFNC or SMO during RSI. HFNC was maintained throughout the intubation procedure whereas SMO was removed to perform laryngoscopy. The primary outcome was the lowest pulse oximetry (SpO2) throughout the intubation procedure. Secondary outcomes included drop in SpO2, adverse events related to intubation, and outcome in the ICU.

RESULTS:

A total of 192 patients were randomized. In the intent-to-treat analysis, 184 patients (HFNC n = 95; SMO n = 89), the median [IQR] lowest SpO2 was 100% [97; 100] for HFNC and 99% [95; 100] for the SMO group (P = 0.30). Mild desaturation below 95% was more frequent with SMO (23%) than with HFNC (12%) (RR 0.51, 95% CI 0.26-0.99, P = 0.045). There were fewer adverse events in the HFNC group (6%) than in the SMO group (19%) (RR 0.31, 95% CI 0.13-0.76, P = 0.007), including fewer severe adverse events, respectively 6 (6%) and 14 (16%) with HFNC and SMO (RR 0.38, 95% CI 0.15-0.95, P = 0.03).

CONCLUSIONS:

Compared with SMO, preoxygenation with HFNC in the ICU did not improve the lowest SpO2 during intubation in the non-severely hypoxemic patients but led to a reduction in intubation-related adverse events.

TRIAL REGISTRATION:

Clinical trial Submission: 7 March 2016. Registry name: Benefits of high-flow nasal cannulae oxygen for preoxygenation during intubation in non-severely hypoxemic patients: the PROTRACH study. Clinicaltrials.gov identifier: NCT02700321. Eudra CT: 2015-A00145-44. CPP: 15/13-975 (Comité de protection des personnes de Rennes). URL registry: https://clinicaltrials.gov/ct2/show/record/NCT02700321 .

KEYWORDS:

Apneic oxygenation; High-flow oxygen therapy by nasal cannulae; Intensive care unit; Intubation; Preoxygenation

PMID:
30666367
DOI:
10.1007/s00134-019-05529-w

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center